GB2563551A - Screening assay using drosophila lines - Google Patents

Screening assay using drosophila lines

Info

Publication number
GB2563551A
GB2563551A GB1815773.5A GB201815773A GB2563551A GB 2563551 A GB2563551 A GB 2563551A GB 201815773 A GB201815773 A GB 201815773A GB 2563551 A GB2563551 A GB 2563551A
Authority
GB
United Kingdom
Prior art keywords
screening assay
drosophila lines
drosophila
lines
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1815773.5A
Other versions
GB201815773D0 (en
Inventor
Zografos Lysimachos
Styczynska-Soczka Katarzyna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parkure Ltd
Original Assignee
Parkure Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parkure Ltd filed Critical Parkure Ltd
Publication of GB201815773D0 publication Critical patent/GB201815773D0/en
Publication of GB2563551A publication Critical patent/GB2563551A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
    • A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
    • A01K67/0337—Genetically modified Arthropods
    • A01K67/0339—Genetically modified insects, e.g. Drosophila melanogaster, medfly
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/203—Animal model comprising inducible/conditional expression system, e.g. hormones, tet
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/70—Invertebrates
    • A01K2227/706—Insects, e.g. Drosophila melanogaster, medfly
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Environmental Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention is concerned with methods of using genetically modified Drosophila to screen chemicals for potential use in treating neurodegenerative conditions, such as Parkinson's disease.
GB1815773.5A 2016-03-02 2017-03-02 Screening assay using drosophila lines Withdrawn GB2563551A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1603654.3A GB201603654D0 (en) 2016-03-02 2016-03-02 Screening assay
PCT/GB2017/050554 WO2017149307A1 (en) 2016-03-02 2017-03-02 Screening assay using drosophila lines

Publications (2)

Publication Number Publication Date
GB201815773D0 GB201815773D0 (en) 2018-11-14
GB2563551A true GB2563551A (en) 2018-12-19

Family

ID=55807200

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1603654.3A Ceased GB201603654D0 (en) 2016-03-02 2016-03-02 Screening assay
GB1815773.5A Withdrawn GB2563551A (en) 2016-03-02 2017-03-02 Screening assay using drosophila lines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB1603654.3A Ceased GB201603654D0 (en) 2016-03-02 2016-03-02 Screening assay

Country Status (2)

Country Link
GB (2) GB201603654D0 (en)
WO (1) WO2017149307A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040194158A1 (en) * 2003-03-28 2004-09-30 Baylor College Of Medicine Model for neurodegenerative disorders
WO2005041650A1 (en) * 2003-10-20 2005-05-12 Envivo Pharmaceuticals, Inc. TRANSGENIC FLIES EXPRESSING MUTANT Aβ42
US20100175140A1 (en) * 2008-12-19 2010-07-08 The Johns Hopkins University Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040194158A1 (en) * 2003-03-28 2004-09-30 Baylor College Of Medicine Model for neurodegenerative disorders
WO2005041650A1 (en) * 2003-10-20 2005-05-12 Envivo Pharmaceuticals, Inc. TRANSGENIC FLIES EXPRESSING MUTANT Aβ42
US20100175140A1 (en) * 2008-12-19 2010-07-08 The Johns Hopkins University Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
S. OTT, N. DZIADULEWICZ, D. C. CROWTHER: "Iron is a specific cofactor for distinct oxidation- and aggregation-dependent A� toxicity mechanisms in a Drosophila model", DISEASE MODELS & MECHANISMS, THE COMPANY OF BIOLOGISTS LTD., GB, vol. 8, no. 7, 1 July 2015 (2015-07-01), GB, pages 657 - 667, XP055368692, ISSN: 1754-8403, DOI: 10.1242/dmm.019042 *
Z. LIU, S. HAMAMICHI, B. DAE LEE, D. YANG, A. RAY, G. A. CALDWELL, K. A. CALDWELL, T. M. DAWSON, W. W. SMITH, V. L. DAWSON: "Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, GB, vol. 20, no. 20, 15 October 2011 (2011-10-15), gb, pages 3933 - 3942, XP055370577, ISSN: 0964-6906, DOI: 10.1093/hmg/ddr312 *
Z. LIU, X. WANG, Y. YU, X. LI, T. WANG, H. JIANG, Q. REN, Y. JIAO, A. SAWA, T. MORAN, C. A. ROSS, C. MONTELL, W. W. SMITH: "A Drosophila model for LRRK2-linked parkinsonism", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, NATIONAL ACADEMY OF SCIENCES, US, vol. 105, no. 7, 19 February 2008 (2008-02-19), US, pages 2693 - 2698, XP055368622, ISSN: 0027-8424, DOI: 10.1073/pnas.0708452105 *

Also Published As

Publication number Publication date
WO2017149307A1 (en) 2017-09-08
GB201815773D0 (en) 2018-11-14
GB201603654D0 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
WO2016100162A3 (en) 5,5-bicyclic oxazole orexin receptor antagonists
EA202091540A1 (en) ANTIBODIES TO LILRB2
TR201901445T4 (en) Il2rbeta / common gamma chain antibodies.
WO2016100157A3 (en) 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
MX2019003623A (en) Compositions and methods for treating ophthalmic conditions.
EA201790806A1 (en) IMMUNOREGULATING AGENTS
EA201992546A1 (en) MEANS ON THE BASIS OF ANTIBODIES TO CD33
EP4218832A3 (en) Methods and compositions for 18f-radiolabeling of the fibronectin type (iii) domain
GEP20207151B (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
ZA201902141B (en) Acid-alpha glucosidase variants and uses thereof
CR20170060A (en) ANTI TIGIT ANTIBODIES
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
PE20180024A1 (en) TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS
BR112016028045A2 (en) MODIFIED BIOPOLYMERS, AND THEIR PRODUCTION METHODS
EA201891539A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EA201691568A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS OF ANTAGONISTS ANDROGEN RECEPTORS
JO3316B1 (en) 3,4-dihydroisoquinolin-2(1h)-yl compounds
PH12019500376A1 (en) Acid-alpha glucosidase variants and uses thereof
JO3576B1 (en) Antibodies to tau and uses thereof
PH12017500920B1 (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazine as modulators of gpr139
WO2015106273A3 (en) Methods and assays relating to huntingtons disease and parkinson's disease
MX2018011622A (en) Pyrimidines and variants thereof, and uses therefor.
WO2017066712A3 (en) Modulators of telomere disease
MY182924A (en) Enzyme compositions and uses thereof

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)